About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Slc22a1tm1Ahs
targeted mutation 1, Alfred H Schinkel
MGI:2182947
Summary 2 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
hm1
Slc22a1tm1Ahs/Slc22a1tm1Ahs involves: 129P2/OlaHsd * FVB MGI:4438878
cx2
Slc22a1tm1Ahs/Slc22a1tm1Ahs
Slc22a2tm2Ahs/Slc22a2tm2Ahs
involves: 129P2/OlaHsd * FVB MGI:2680275


Genotype
MGI:4438878
hm1
Allelic
Composition
Slc22a1tm1Ahs/Slc22a1tm1Ahs
Genetic
Background
involves: 129P2/OlaHsd * FVB
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Slc22a1tm1Ahs mutation (0 available); any Slc22a1 mutation (29 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
homeostasis/metabolism
• at 20 min after i.v. administration of [14C]-TEA (0.2 mg/kg), homozygotes show a 1.5-fold increase in the amount of TEA found in urine relative to wild-type controls
• at 60 min after i.v. administration of [14C]-TEA (0.2 mg/kg), fully anesthetized homozygotes with a cannulated gallbladder show a similar 1.5-fold increase in cumulative excretion of [14C]-TEA in urine relative to wild-type controls
• at 20 min after i.v. administration of 0.2 mg/kg [14C]-tetraethylammonium (TEA; a model compound for small, relatively hydrophilic cations), homozygotes show a >6-fold reduction of [14C]-TEA accumulation in the liver relative to wild-type controls; however, no significant differences in TEA levels are detected in brain, spleen or plasma relative to similarly treated wild-type controls
• at 60 min after i.v. injection of [14C]-TEA (0.2 mg/kg), fully anesthetized homozygotes with a cannulated gallbladder show a ~4-fold reduction of [14C]-TEA accumulation in the liver relative to wild-type controls; however, levels of [14C]-TEA in cecum and colon contents are similar to those in wild-type controls
• at 60 min after i.v. administration of [14C]-TEA (0.2 mg/kg), fully anesthetized homozygotes with a cannulated gallbladder show a 2.5-fold decrease in cumulative excretion of [14C]-TEA in bile relative to wild-type controls
• at 20 min after i.v. administration of [14C]-TEA (0.2 mg/kg), homozygotes show a 6- to 10-fold reduction of TEA excretion levels into the lumen of the small intestine, cecum, and colon relative to wild-type controls
• at 20 min after i.v. administration of [14C]-TEA (0.2 mg/kg), homozygotes show a 1.5-fold increase in the amount of TEA found in urine relative to wild-type controls
• at 60 min after i.v. administration of [14C]-TEA (0.2 mg/kg), fully anesthetized homozygotes with a cannulated gallbladder show a similar 1.5-fold increase in cumulative excretion of [14C]-TEA in urine relative to wild-type controls
• at 60 min after i.v. injection of [14C]TEA (0.2 mg/kg), fully anesthetized homozygotes with a cannulated gallbladder show a 2-fold decrease in direct small intestinal excretion of [14C]TEA relative to wild-type controls
• at 30 min after i.v. administration of [3H]MPP+ (a neurotoxin) or [125I]MIBG (an anticancer drug), each at 1 mg/kg, hepatic uptake of [3H]MPP+ and [125I]MIBG is reduced ~60% and 75%, respectively; however, no differences in plasma, spleen, or small intestinal excretion of these organic cations are observed relative to similarly treated wild-type controls
• no significant differences are observed following i.v. administration in the distribution of [3H]cimetidine and [14C]choline to the liver or other organs

liver/biliary system
• at 60 min after i.v. administration of [14C]-TEA (0.2 mg/kg), fully anesthetized homozygotes with a cannulated gallbladder show a 2.5-fold decrease in cumulative excretion of [14C]-TEA in bile relative to wild-type controls
• at 20 min after i.v. administration of [14C]-TEA (0.2 mg/kg), homozygotes show a >6-fold reduction of [14C]-TEA accumulation in the liver relative to wild-type controls; however, no significant differences in TEA levels are detected in brain, spleen or plasma relative to similarly treated wild-type controls
• at 60 min after i.v. injection of [14C]-TEA (0.2 mg/kg), fully anesthetized homozygotes with a cannulated gallbladder show a ~4-fold reduction of [14C]-TEA accumulation in the liver relative to wild-type controls; however, levels of [14C]-TEA in cecum and colon contents are similar to those in wild-type controls
• at 30 min after i.v. administration of [3H]MPP+ (a neurotoxin) or [125I]MIBG (an anticancer drug), each at 1 mg/kg, hepatic uptake of [3H]MPP+ and [125I]MIBG is reduced ~60% and 75%, respectively; however, no differences in plasma, spleen, or small intestinal excretion of these organic cations are observed relative to similarly treated wild-type controls
• no significant differences are observed following i.v. administration in the distribution of [3H]cimetidine and 14C]choline to the liver or other organs

digestive/alimentary system
• at 20 min after i.v. administration of [14C]-TEA (0.2 mg/kg), homozygotes show a 6- to 10-fold reduction of TEA excretion levels into the lumen of the small intestine, cecum, and colon relative to wild-type controls
• at 60 min after i.v. injection of [14C]TEA (0.2 mg/kg), fully anesthetized homozygotes with a cannulated gallbladder show a 2-fold decrease in direct small intestinal excretion of [14C]TEA relative to wild-type controls

renal/urinary system
• at 20 min after i.v. administration of [14C]-TEA (0.2 mg/kg), homozygotes show a 1.5-fold increase in the amount of TEA found in urine relative to wild-type controls
• at 60 min after i.v. administration of [14C]-TEA (0.2 mg/kg), fully anesthetized homozygotes with a cannulated gallbladder show a similar 1.5-fold increase in cumulative excretion of [14C]-TEA in urine relative to wild-type controls




Genotype
MGI:2680275
cx2
Allelic
Composition
Slc22a1tm1Ahs/Slc22a1tm1Ahs
Slc22a2tm2Ahs/Slc22a2tm2Ahs
Genetic
Background
involves: 129P2/OlaHsd * FVB
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Slc22a1tm1Ahs mutation (0 available); any Slc22a1 mutation (29 available)
Slc22a2tm2Ahs mutation (0 available); any Slc22a2 mutation (39 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
renal/urinary system
• impaired renal secretion of small organic cations

homeostasis/metabolism
• impaired renal secretion of small organic cations





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
03/19/2024
MGI 6.23
The Jackson Laboratory